Phototherapy 660 nm for the prevention of radiodermatitis in breast cancer patients receiving radiation therapy: study protocol for a randomized controlled trial

Página do item simplificado
dc.contributor.authorCosta, Marina Moreira
dc.contributor.authorSilva, Sidney Benedito
dc.contributor.authorQuinto, Ana Luiza Pereira
dc.contributor.authorPasquinelli, Priscilla Furtado Souza
dc.contributor.authorSantos, Vanessa de Queiroz dos
dc.contributor.authorSantos, Gabriela de Cassia
dc.contributor.authorVeiga, Daniela Francescato [UNIFESP]
dc.contributor.institutionHosp Canc Barretos
dc.contributor.institutionUniv Vale Sapuca
dc.contributor.institutionOncominas
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:37:44Z
dc.date.available2016-01-24T14:37:44Z
dc.date.issued2014-08-20
dc.description.abstractBackground: Breast neoplasms are the second most common type of cancer worldwide, and radiation therapy is a key component of their treatment. Acute skin reactions are one of the most common side effects of radiation therapy, and prevention of this adverse event has been investigated in several studies. However, a clinically applicable, preventative treatment remains unavailable. It has been demonstrated that application of a low-power laser can promote tissue repair. Therefore, the aim of this trial is to evaluate the effectiveness of an indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm in preventing radiodermatitis in women undergoing adjuvant radiotherapy for breast cancer.Methods/Design: This is a two-arm, randomized controlled trial. A total of 52 patients undergoing radiotherapy for breast cancer (stages I to III) will be enrolled. Patients will be randomly assigned to an intervention group to receive laser therapy (n = 26) or a control group to receive a placebo (n = 26). the laser or placebo will be applied five days a week, immediately before each radiotherapy session. Skin reactions will then be graded weekly by a nurse, a radiotherapist, and an oncologist (all of whom will be blinded) using the Common Toxicity Criteria (CTC) developed by the National Cancer Institute and the Acute Radiation Morbidity Scoring Criteria developed by the Radiation Therapy Oncology Group. Patients will also answer a modified visual analogue scale for pain (a self-evaluation questionnaire). Primary and secondary outcomes will be the prevention of radiodermatitis and pain secondary to radiodermatitis, respectively.Discussion: the ideal tool for preventing radiodermatitis is an agent that mediates DNA repair or promotes cell proliferation. Application of a low-power laser has been shown to promote tissue repair by reducing inflammation and inducing collagen synthesis. Moreover, this treatment approach has not been associated with adverse events and is cost-effective. Thus, the results of this ongoing trial may establish whether use of a low-power laser represents an ideal treatment option for the prevention of radiodermatitis.en
dc.description.affiliationHosp Canc Barretos, Dept Oncol, BR-14784400 Barretos, SP, Brazil
dc.description.affiliationUniv Vale Sapuca, Dept Physiotherapy, BR-37550000 Pouso Alegre, MG, Brazil
dc.description.affiliationHosp Canc Barretos, Dept Radiotherapy, BR-14784400 Barretos, SP, Brazil
dc.description.affiliationOncominas, Dept Radiotherapy, BR-37550 Pouso Alegre, MG, Brazil
dc.description.affiliationUniv Vale Sapuca, Dept Plast Surg, BR-37550000 Pouso Alegre, MG, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Plast Surg, BR-04024002 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Plast Surg, BR-04024002 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent6
dc.identifierhttp://dx.doi.org/10.1186/1745-6215-15-330
dc.identifier.citationTrials. London: Biomed Central Ltd, v. 15, 6 p., 2014.
dc.identifier.doi10.1186/1745-6215-15-330
dc.identifier.fileWOS000340789400001.pdf
dc.identifier.issn1745-6215
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/38098
dc.identifier.wosWOS:000340789400001
dc.language.isoeng
dc.publisherBiomed Central Ltd
dc.relation.ispartofTrials
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBreast neoplasmsen
dc.subjectLaser therapyen
dc.subjectLow-levelen
dc.subjectRadiodermatitisen
dc.subjectPrevention & controlen
dc.titlePhototherapy 660 nm for the prevention of radiodermatitis in breast cancer patients receiving radiation therapy: study protocol for a randomized controlled trialen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000340789400001.pdf
Tamanho:
450.33 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
Em verificação - Geral